{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:23:59Z","timestamp":1793413439977,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.cgh.2022.05.042","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T22:27:28Z","timestamp":1655850448000},"page":"723-731.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Dosing of Rifaximin Soluble Solid Dispersion Tablets in Adults With Cirrhosis: 2 Randomized, Placebo-controlled Trials"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4928-3681","authenticated-orcid":false,"given":"Jasmohan S.","family":"Bajaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek I.","family":"Hassanein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos T.","family":"Pyrsopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Rahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeev","family":"Heimanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Israel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don C.","family":"Rockey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2022.05.042_bib1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/MCG.0000000000000826","article-title":"Early hospital readmissions and mortality in patients with decompensated cirrhosis enrolled in a large national health insurance administrative database","volume":"51","author":"Scaglione","year":"2017","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2022.05.042_bib2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/hep.27210","article-title":"Hepatic encephalopathy in\u00a0chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver","volume":"60","author":"Vilstrup","year":"2014","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2022.05.042_bib3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000081991","article-title":"Rifaximin: in\u00a0vitro and in\u00a0vivo antibacterial activity\u2013a review","volume":"51","author":"Jiang","year":"2005","journal-title":"Chemotherapy"},{"key":"10.1016\/j.cgh.2022.05.042_bib4","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/hep.31708","article-title":"The use of rifaximin in patients with cirrhosis","volume":"74","author":"Caraceni","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.05.042_bib5","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy","volume":"362","author":"Bass","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2022.05.042_bib6","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.cgh.2013.12.021","article-title":"Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy","volume":"12","author":"Mullen","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.05.042_bib7","series-title":"Xifaxan (rifaximin) tablets, for oral use","year":"2020"},{"key":"10.1016\/j.cgh.2022.05.042_bib8","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1128\/AAC.00161-10","article-title":"Bile acids improve the antimicrobial effect of rifaximin","volume":"54","author":"Darkoh","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cgh.2022.05.042_bib9","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jhep.2013.01.003","article-title":"Modulation of the fecal bile acid profile by gut microbiota in cirrhosis","volume":"58","author":"Kakiyama","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2022.05.042_bib10","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s11011-016-9851-9","article-title":"Overt hepatic encephalopathy: development of a novel clinician reported outcome tool and electronic caregiver diary","volume":"31","author":"Bajaj","year":"2016","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.cgh.2022.05.042_bib11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D\u2019Amico","year":"2006","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2022.05.042_bib12","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/MEG.0000000000001822","article-title":"Risk of recurrent hepatic encephalopathy in patients with liver cirrhosis: a German registry study","volume":"33","author":"Gabriel","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.05.042_bib13","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0168-8278(99)80144-5","article-title":"Prognostic significance of hepatic encephalopathy in patients with cirrhosis","volume":"30","author":"Bustamante","year":"1999","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2022.05.042_bib14","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1111\/hepr.13207","article-title":"Microbiome and bile acid profiles in duodenal aspirates from patients with liver cirrhosis: the Microbiome, Microbial Markers and Liver Disease Study","volume":"48","author":"Jacobs","year":"2018","journal-title":"Hepatol Res"},{"key":"10.1016\/j.cgh.2022.05.042_bib15","article-title":"Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology","volume":"6","author":"Chen","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.cgh.2022.05.042_bib16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nature13568","article-title":"Alterations of the human gut microbiome in liver cirrhosis","volume":"513","author":"Qin","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.cgh.2022.05.042_bib17","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1038\/s41467-020-18754-5","article-title":"Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD","volume":"11","author":"Lee","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.cgh.2022.05.042_bib18","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jhep.2013.12.019","article-title":"Altered profile of human gut microbiome is associated with cirrhosis and its complications","volume":"60","author":"Bajaj","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2022.05.042_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060042","article-title":"Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy","volume":"8","author":"Bajaj","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2022.05.042_bib20","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/apt.15326","article-title":"Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list","volume":"50","author":"Salehi","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.05.042_bib21","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1111\/apt.15265","article-title":"Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort","volume":"49","author":"Bajaj","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.05.042_bib22","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1007\/s10620-020-06051-6","article-title":"Cirrhotic patients on mechanical ventilation have a low rate of successful extubation and survival","volume":"65","author":"Sasso","year":"2020","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2022.05.042_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(20)34307-9","article-title":"Rifaximin soluble solid dispersion tablets modify gut microbial function, as shown by increased fecal secondary bile acid levels compared with placebo, in patients with early decompensated cirrhosis","volume":"158","author":"Kakiyama","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.05.042_bib24","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1053\/j.gastro.2018.12.005","article-title":"International Club of Ascites Global Study Group. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide","volume":"156","author":"Piano","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.05.042_bib25","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jhep.2019.06.010","article-title":"Another clinical unmet need in liver patients: multidrug resistant bacteria in decompensated cirrhosis","volume":"71","author":"Morais","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2022.05.042_bib26","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1053\/j.gastro.2007.06.065","article-title":"Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis","volume":"133","author":"Fernandez","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.05.042_bib27","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s11011-016-9851-9","article-title":"Overt hepatic encephalopathy: development of a novel clinician reported outcome tool and electronic caregiver diary","volume":"31","author":"Bajaj","year":"2016","journal-title":"Metab Brain Dis"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154235652200595X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154235652200595X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:41:07Z","timestamp":1761543667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154235652200595X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S154235652200595X"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2022.05.042","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dosing of Rifaximin Soluble Solid Dispersion Tablets in Adults With Cirrhosis: 2 Randomized, Placebo-controlled Trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2022.05.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the AGA Institute. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}